Condition
Classic Kaposi Sarcoma
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Withdrawn2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05846724Phase 2Withdrawn
Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma
NCT03219671Phase 2UnknownPrimary
Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)
NCT00521092Phase 2Withdrawn
Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
Showing all 3 trials